Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox 4 like 20 (DUX4L20) is classified as a pseudogene in humans, meaning it arises from a duplication of a related gene (DUX4) but does not encode a functional protein product[4]. DUX4L20 has sequence similarity to DUX4, a transcription factor involved in embryonic development and also implicated in facioscapulohumeral muscular dystrophy (FSHD)[1][5], but DUX4L20 itself is not known to have any biological function, interact with drugs, or serve as a therapeutic target. There is no evidence that DUX4L20 plays a role in physiological or disease processes nor that it encodes a functional protein[4]. Its presence is sometimes mentioned in genetic studies due to shared ancestry with DUX4. Clarification: The protein-coding DUX4 gene/protein (not DUX4L20) is a recognized transcription factor and is being studied as a therapeutic target, particularly in cancer and muscular dystrophy[1][2][3][5]. If your interest is in the biologically active molecule, you should refer to Double homeobox 4 (DUX4), not "Double homeobox 4 like 20" (DUX4L20). DUX4L20 is a non-functional pseudogene and not relevant as a therapeutic or biological target[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox 4 like 20 (DUX4L20).